Intersect ENT Appoints David Lehman General Counsel

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced the appointment of David Lehman as general counsel. Mr. Lehman brings three decades of legal experience to Intersect ENT, most recently having served as general counsel and secretary for Thoratec Corporation (NASDAQ:THOR), a global leader in medical technology to address advanced-stage heart failure, where he saw the company through tremendous growth and eventual sale to St. Jude Medical.

"He is an accomplished attorney and executive with substantial global experience. I look forward to partnering with David as we work to build Intersect ENT into the preeminent ENT company."
"I am excited to welcome David to our leadership team as our first general counsel," said Lisa Earnhardt, president and chief executive officer of Intersect ENT. "He is an accomplished attorney and executive with substantial global experience. I look forward to partnering with David as we work to build Intersect ENT into the preeminent ENT company."

"Intersect ENT's story has been fun to watch and I'm excited to become part of the team. This is a wonderful opportunity to join a business with strong opportunities for growth and expansion. I am looking forward to working with Lisa, the executive team, and the Intersect ENT board to help build on the company's many successes," said Mr. Lehman.

About Intersect ENT

Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets two steroid releasing implants, PROPEL® and PROPEL® mini, clinically proven to improve surgical outcomes for patients with chronic sinusitis undergoing ethmoid sinus surgery. In addition, Intersect ENT is developing new steroid releasing implants designed to provide ENT physicians with even more customized options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers.

For additional information on the company or the products including risks and benefits please visit www.intersectENT.com.

Forward-Looking Statements

The statements in this press release regarding our ability to build the company into the preeminent ENT company and the outlook for strong growth and expansion are "forward-looking" statements. These forward-looking statements are based on Intersect ENT's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, which include, without limitation, the performance of PROPEL and PROPEL mini, the development of competitive products, the uncertain timing of completion of and the success of clinical trials and market competition. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Intersect ENT's filings on Form 10-K, Form 10-Q and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov). Intersect ENT does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

XENT-G

Contacts

Intersect ENT, Inc.
Jeri Hilleman, 650-641-2105
[email protected]
Nicole Osmer, 650-454-0504
[email protected]
 

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.